{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:23:58Z","timestamp":1785536638969,"version":"3.56.0"},"reference-count":55,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,11,14]],"date-time":"2013-11-14T00:00:00Z","timestamp":1384387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[2014,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Previous research indicated that coeliac disease (<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>) is associated with type 1 diabetes mellitus (T1<jats:styled-content style=\"fixed-case\">DM<\/jats:styled-content>). However, the gut\u2010brain axis peptide hormones secretion has not been evaluated so far in patients with <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content> prior to treatment initiation or under treatment, irrespective of patients having concomitant T1<jats:styled-content style=\"fixed-case\">DM<\/jats:styled-content> or not. The aim of the study was therefore to evaluate these gut hormones at the preprandial levels of patients with <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content> before and under treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Of forty\u2010seven <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content> children, 12 untreated (<jats:styled-content style=\"fixed-case\">UCD<\/jats:styled-content>), 22 treated with gluten\u2010free diet (<jats:styled-content style=\"fixed-case\">TCD<\/jats:styled-content>) and 13 treated <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content> with coexisting T1<jats:styled-content style=\"fixed-case\">DM<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">DCD<\/jats:styled-content>), and 18 healthy controls (<jats:styled-content style=\"fixed-case\">HC<\/jats:styled-content>) were enrolled. Preprandial glucagon\u2010like\u2010peptide\u20101 (<jats:styled-content style=\"fixed-case\">GLP<\/jats:styled-content>\u20101), glucose\u2010dependent\u2010insulinotropic\u2010polypeptide (<jats:styled-content style=\"fixed-case\">GIP<\/jats:styled-content>), active amylin, acylated ghrelin (<jats:styled-content style=\"fixed-case\">AG<\/jats:styled-content>), leptin, pancreatic polypeptide (<jats:styled-content style=\"fixed-case\">PP<\/jats:styled-content>) and peptide\u2010tyrosine\u2010tyrosine (<jats:styled-content style=\"fixed-case\">PYY<\/jats:styled-content>) were determined with hormone\u2010map\u2010array technology.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We found in patients with <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content> compared with <jats:styled-content style=\"fixed-case\">HC<\/jats:styled-content> that the concentration of (i) <jats:styled-content style=\"fixed-case\">GLP<\/jats:styled-content>\u20101 was reduced remarkably in all patients with <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content> (<jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7008), (ii) <jats:styled-content style=\"fixed-case\">GIP<\/jats:styled-content> was lower in patients with <jats:styled-content style=\"fixed-case\">UCD<\/jats:styled-content> (<jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7008), (iii) amylin was remarkably reduced (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b701) in all patients with <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>, (iv) <jats:styled-content style=\"fixed-case\">AG<\/jats:styled-content> was significantly decreased in patients with <jats:styled-content style=\"fixed-case\">DCD<\/jats:styled-content> (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b701), while (v) leptin, <jats:styled-content style=\"fixed-case\">PP<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">PYY<\/jats:styled-content> were not significantly different. <jats:styled-content style=\"fixed-case\">GIP<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> GLP<\/jats:styled-content>\u20101 and amylin levels correlated positively with insulin concentrations (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b7001, <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7004 and <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b701, respectively) in all patients. Amylin and <jats:styled-content style=\"fixed-case\">GIP<\/jats:styled-content> levels were strongly associated with triglycerides concentrations (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b7001, for both peptides) in children with <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our study revealed a different secretion pattern of gut\u2010brain axis hormones in children with <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content> compared with <jats:styled-content style=\"fixed-case\">HC<\/jats:styled-content>. The alterations in the axis were more pronounced in children with both <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content> and T1<jats:styled-content style=\"fixed-case\">DM<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/eci.12193","type":"journal-article","created":{"date-parts":[[2013,10,24]],"date-time":"2013-10-24T06:40:07Z","timestamp":1382596807000},"page":"74-82","source":"Crossref","is-referenced-by-count":14,"title":["Incretins, amylin and other gut\u2010brain axis hormones in children with coeliac disease"],"prefix":"10.1111","volume":"44","author":[{"given":"Maria","family":"Papastamataki","sequence":"first","affiliation":[{"name":"Department of Clinical Biochemistry \u2018Aghia Sophia\u2019 Children's Hospital Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Papassotiriou","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry \u2018Aghia Sophia\u2019 Children's Hospital Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Bartzeliotou","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry \u2018Aghia Sophia\u2019 Children's Hospital Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andriani","family":"Vazeou","sequence":"additional","affiliation":[{"name":"First Department of Pediatrics \u2018P&amp;A Kyriakou\u2019, Children's Hospital Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftheria","family":"Roma","sequence":"additional","affiliation":[{"name":"First Department of Pediatrics University of Athens School of Medicine Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George P.","family":"Chrousos","sequence":"additional","affiliation":[{"name":"First Department of Pediatrics University of Athens School of Medicine Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Kanaka\u2010Gantenbein","sequence":"additional","affiliation":[{"name":"First Department of Pediatrics University of Athens School of Medicine Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,11,14]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra071600"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14027-5"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2008.01741.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411243312107"},{"key":"e_1_2_8_6_1","doi-asserted-by":"crossref","first-page":"647","DOI":"10.33549\/physiolres.931995","article-title":"Gut peptide hormones and pediatric type 1 diabetes mellitus","volume":"60","author":"Huml M","year":"2011","journal-title":"Physiol Res"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2006.12.046"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807917"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1515\/JPEM.2007.20.12.1257"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.04037.x"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2006.11.007"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0706890104"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI30227"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05484"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2012.01.007"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.108.000604"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI30076"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2006"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-010-1896-4"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2826.2006.01492.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.4.1056"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2009.06.010"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01670.x"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2006.04.001"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-24716-3_10"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00333.2003"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.1.8129"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-020645"},{"key":"e_1_2_8_29_1","first-page":"774","article-title":"Increased plasma ghrelin level in lung cancer cachexia","volume":"9","author":"Shimizu Y","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.50.4.707"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2012.04.007"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1442-200X.2003.01787.x"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0899-9007(99)00177-X"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-9781(01)00601-5"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2006.09.024"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1980.tb03407.x"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2011.10.008"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1425"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1159\/000116770"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S7556"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yapd.2008.07.001"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2012.06.016"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.6.1294"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200602000-00013"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-60-1-120"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1988.tb15895.x"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.4.1100"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365520510012028"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200603000-00004"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07709.x"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02852.x"},{"key":"e_1_2_8_52_1","first-page":"CR533","article-title":"Insulin treatment reduces pre\u2010prandial plasma ghrelin concentrations in children with type 1 diabetes","volume":"13","author":"Ashraf A","year":"2007","journal-title":"Med Sci Monit"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1695-4033(01)77666-7"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mcg.0000225513.20913.6a"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1159\/000096422"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012344424300"}],"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Feci.12193","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/eci.12193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T01:18:48Z","timestamp":1696295928000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/eci.12193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,14]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["10.1111\/eci.12193"],"URL":"https:\/\/doi.org\/10.1111\/eci.12193","archive":["Portico"],"relation":{},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"value":"0014-2972","type":"print"},{"value":"1365-2362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,14]]}}}